CD44 and breast carcinoma: We determined the proportions of putative CSCs with CD44+/CD24− or ALDH1+ phenotypes using immunohistochemistry in pre- and post-chemotherapy breast cancer tissue, and analysed the association between the changes of putative CSC population after PST and clinicopathologic parameters, including patients’ survival.